Temporal dissection of K-rasG12D mutant in vitro and in vivo using a regulatable K-rasG12D mouse allele

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Wang, Zuoyun ^a   Feng, Yan ^a   Bardessy, Nabeel ^b   Wong, Kwok Kin ^c   Liu, Xin Yuan ^a   Ji, Hongbin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN; PRIMER DNA;

ALLELE; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; EMBRYO CELL; FIBROBLAST; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE FUNCTION; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE K RAS; TUMOR REGRESSION; ANIMAL; CELL CULTURE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; MOUSE MUTANT; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; GENES, RAS; LUNG NEOPLASMS; MALE; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTATION; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84860992101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037308     Document Type: Article

References (46)

1. Arnold I, Watt FM, (2001) c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 11: 558-568.
2. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718-726.
3. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegue E, et al. (2011) Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev 25: 1746-1757.
4. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM,et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567-571.
5. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI, (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10: 501-514.
6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
7. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, et al. (2010) Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468: 572-575.
8. Martins CP, Brown-Swigart L, Evan GI, (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
9. Soucek L, Nasi S, Evan GI, (2004) Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ 11: 1038-1045.
10. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336.
11. Yu D, Carroll M, Thomas-Tikhonenko A, (2007) p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood 109: 4936-4943.
12. Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI, (2009) Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol 29: 5306-5315.
13. Bos JL, (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
14. Croce CM, (2008) Oncogenes and cancer. N Engl J Med 358: 502-511.
15. Rodenhuis S, (1992) ras and human tumors. Semin Cancer Biol 3: 241-247.
16. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, et al. (2009) Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11: 1084-1092.
17. Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, et al. (2007) Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol Rep 18: 623-628.
18. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, et al. (1996) K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56: 2224-2228.
19. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, et al. (2008) RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 10: 680-686, 682 p following 686.
20. Liu L, Zhu S, Gong Z, Low BC, (2008) K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis. PLoS One 3: e2850.
21. Wells V, Downward J, Mallucci L, (2007) Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene 26: 7709-7714.
22. Menges CW, McCance DJ, (2008) Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 27: 2934-2940.
23. Lim KH, Counter CM, (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381-392.
24. Ambesi A, Klein RM, Pumiglia KM, McKeown-Longo PJ, (2005) Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal-regulated kinase and causes G(1) arrest in human microvessel endothelial cells. Cancer Res 65: 148-156.
25. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, et al. (2005) Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 65: 9962-9970.
26. Tarutani M, Cai T, Dajee M, Khavari PA, (2003) Inducible activation of Ras and Raf in adult epidermis. Cancer Res 63: 319-323.
27. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ, (2004) Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468.
28. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
29. Ji HB, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-U807.
30. Gao Y, Xiao Q, Ma H, Li L, Liu J, et al. (2010) LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 107: 18892-18897.
31. Fujimoto K, Arakawa S, Shibaya Y, Miida H, Ando Y, et al. (2006) Characterization of phenotypes in Gstm1-null mice by cytosolic and in vivo metabolic studies using 1,2-dichloro-4-nitrobenzene. Drug Metab Dispos 34: 1495-1501.
32. Blagosklonny MV, (2002) P53: an ubiquitous target of anticancer drugs. Int J Cancer 98: 161-166.
33. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387.
34. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, et al. (1998) RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer 21: 270-275.
35. Quinlan MP, Quatela SE, Philips MR, Settleman J, (2008) Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol.
36. Kohno T, Kunitoh H, Suzuki K, Yamamoto S, Kuchiba A, et al. (2008) Association of KRAS Polymorphisms with Risk for Lung Adenocarcinoma Accompanied by Atypical Adenomatous Hyperplasias. Carcinogenesis.
37. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
38. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
39. Mukhopadhyay A, Krishnaswami SR, Yu BD, (2011) Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol 131: 311-319.
40. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, et al. (2009) TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 136: 1680-1688 e1687.
41. Osborne CK, Hobbs K, Clark GM, (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584-590.
42. Briand P, Lykkesfeldt AE, (1986) Long-term cultivation of a human breast cancer cell line, MCF-7, in a chemically defined medium. Effect of estradiol. Anticancer Res 6: 85-90.
43. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, et al. (2009) Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 4: 427-439.
44. Pelengaris S, Khan M, Evan GI, (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
45. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, et al. (2009) HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119: 2160-2170.
46. Hammoud Z, Tan B, Badve S, Bigsby RM, (2008) Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15: 475-483.